Reported about 24 hours ago
This month presents a compelling opportunity to invest in CRISPR Therapeutics and Moderna, two innovative biotech companies that have encountered challenges this year, with their stocks down 27% and 41% respectively. CRISPR has recently gained FDA approval for its groundbreaking gene therapy, Casgevy, which targets sickle cell disease, promising significant growth potential despite current market underperformance. Meanwhile, Moderna is gaining momentum with new products, including a promising combination COVID/flu vaccine and several candidates in late-stage trials, positioning the company for recovery. Both stocks are highlighted as strong buys as they navigate through their respective transitions.
Source: YAHOO